Anesthetic management of patients with coronary stents Dr. S. Parthasarathy MD, DA, DNB, Dip Diab.MD,DCA, Dip software based statistics, PhD (physiology)

Slides:



Advertisements
Similar presentations
Unstable angina and NSTEMI
Advertisements

Blood Pressure.
Single Center Experience with Drug Eluting Stents for Infrapopliteal Occlusive Disease in Patients with Critical Limb Ischemia: Mid-term follow up Robert.
M YOCARDIAL ISCHEMIA Prepared by: Dr. Nehad Ahmed.
Peri-Operative Management of Drug Eluting Stents
ANAESTHESIA AND ANTICOAGULANTS
Update on the Medical Management of Acute Coronary Syndrome.
ANESTHESIA FOR NON CARDIAC SURGERY IN PATIENTS WITH CORONARY STENTS
Asymptomatic Carotid Surgery Trial ACST-2 Collaborators Meeting 2014 Pembroke College, Oxford Is recent coronary stenting a problem (or an opportunity)
CORONARY CIRCULATION DR. Eman El Eter.
Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.
Risks & Prevention for Young Adults Cardiovascular Disease Kristen Hinners.
Antiplatelet therapy in CAD MINILECTURE. Objectives Indications for Antiplatelet Therapy in patients with CAD and ACS Antiplatelet Therapy in the role.
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
Stenting: Function, Problems, and Procedure. Uses for Stents  Peripheral artery disease (PAD)  Renal vascular hypertension  Hemodialysis access maintenance.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.
GP Railway Workshops Heart Week Event Dr Chris Judkins MBBS MClinRes FRACP Interventional Cardiologist WA Cardiology Fiona Stanley.
CORONARY CIRCULATION DR. Eman El Eter. Coronary Arteries The major vessels of the coronary circulation are: 1- left main coronary that divides into left.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
TUESDAY 19TH OCTOBER2010 CATH LAB PRESENTATION. TAO /ACS study STUDY NUMBER: EFC6204 Randomized, double-blind, triple-dummy trial to compare the efficacy.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
One patient, two years, three choices, four PCI ZHAO Peng Cardiology , the Affiliated Hospital of Medical College of CPAPF, Tianjin, China.
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention Stents,adjunctive devices and antithrombotics Presented by ELSayed Farag MD,FSCAI.
Diagnosis, Management, & Follow-up Care Of CAD/AMI BARRY BERTOLET, MD CARDIOLOGY ASSOCIATES OF NORTH MS.
Antiplatelets, Anticoagulants What are the consequences Dr Jeremy Wright Cardiologist Hearts1st, Greenslopes Private Hospital.
Coronary Stents By: Brian Volpe. Coronary Heart Disease (CHD) is the narrowing and blockage of the coronary arteries that supply the heart with blood.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Stent thrombosis, an old souvenir? January 15 th, h30.
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Multivessel Coronary Artery Disease
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
LOGO Presenter : S.Mohammad Zargar Supervisor : Dr. Mahdikhani Faculty of Engineering Department of Biomedical Engineering.
Use of OCT in Determining Dual Antiplatelet Treatment Duration
DRug Eluting Bbsorbable Metal Scaffold (DREAMS)
The management of anti-thrombotics in patients undergoing GI endoscopy
Anticoagulation after peripheral Vascular Intervention
The American College of Cardiology Presented by Dr. Adnan Kastrati
Randomisation before planned PCI with DES (n=2500)
Antithrombotic Therapy in Atrial Fibrillation
One DES Eluting Two Drugs: Is it Feasible?
Management of ST-Elevation Myocardial Infarction
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Glenn N. Levine et al. JACC 2016;68:
Glenn N. Levine et al. JACC 2016;68:
Terms of Use. Terms of Use.
Section F: Clinical guidelines
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction  P.-G. Chassot, A. Delabays, D.R. Spahn 
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
Erasmus MC, Thoraxcenter
European Society of Cardiology Scientific Congress, September 2006
Roberta Rossini et al. JCIN 2018;11:
Recent advances – levosimendan
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Drug-eluting coronary stent market overview
Presentation transcript:

Anesthetic management of patients with coronary stents Dr. S. Parthasarathy MD, DA, DNB, Dip Diab.MD,DCA, Dip software based statistics, PhD (physiology) FICA

What is this ?? In the 1980s the primary management of ACS was thrombolysis Switched over to primary PCI and stents in this decade !!

Types of stents In 1986, French researchers implanted the first stent into a human coronary artery. In 1994, the FDA approved the first heart stent for use in the U.S. First-generation stents were made of bare metal. Bare- metal stents almost eliminated the risk of the artery collapsing. About 25% of all coronary arteries treated with bare- metal stents would close up again, usually within about six months.

Three types now Bare metal – cobalt chromium alloy wire mesh DES - cobalt chromium alloy wire mesh + polymer with sirolimus or paclitaxel (Antiproliferative) Bio absorbable special polymer + drug

Why do we want DES and ?? Bare metal stents are associated with restenosis in 30 % within 3 months We add sirolimus to prevent intimal hyperplasia and restenosis What’s the price ?? Damaged vessel is still exposed – antiplatelet necessary for more time !!

BMS

DES Re stenosis is less Anticoagulation is a must. Dual antiplatelet therapy – must Restenosis 30 % to 5- 8 % after DES ELUTE - - to wash out or extract; specifically : to remove (adsorbed material) from an adsorbent by means of a solvent.

Bioabsorbable – months to a few years Magnesium alloy Polycarbonate Polyopronate Igaki-Tamai bioabsorbable stent. Heparin coated stent don’t elute !!

Bms Bms DESDES

Coronary artery stenting and noncardiac surgery Better to avoid PCI and stenting before elective surgery BMS – minimum 4 weeks DES – one year

2 weeks, 6 weeks, 1 year

Surgery !! ?? Competition stopping DAPT and stent thrombosis And bleeding episodes 5 % patients come for surgery within one year Going on increasing !!

Urgent surgery after stenting Cardiology, anes and surgeon as a team DAPT may continue The plan to stop clopidogrel means – atleast five days Ticagrelor, is reported to have a shorter half-life may offer a slight advantage in the future over clopidogrel when more rapid reversal of antiplatelet effect is required Heparin ?? ( antiplatelet ?? )

Tirofiban and eptifibatide are administered parenterally, have half lives < 2 h, and are eliminated by renal clearance. Platelet function returns to 60% - 90% of normal after the infusion is stopped for 6 – 8 h. Cangrelor – newer antiplatelet drug as bridging therapy

The most serious complication is acute stent thrombosis. This is often due to under deployment of stents with a lack of stent strut apposition to the vessel wall interruption of dual antiplatelet therapy May be 40 % mortality

The rates of coronary stent-related complications in patients undergoing non- cardiac surgery range from 0.6% to 45%, with a mortality rate of 2.6–4.9%. Stents with atrial fibrillation Warfarin to keep INR around 2

Three strategies Continue dual antiplatelet Stop clopidogrel,bridge with other drugs continue aspirin Stop clopidogrel, continue aspirin— Restart with clopidogrel 600 mg as soon as the surgeon permits

On clopidogrel ( not stopped for atleast 5 days ) No neuraxial blocks No catheters Peripheral blocks USG guided acceptable Deep blocks – no Stress reduction !!

On anticoagulants

NO NO ? OK ? OK

In stent restenosis is insidious Stent thrombosis is acute and catastrophic

Risk factors for thrombosis Diabetes ( insulin treated ) Lesion more than 28 mm Left main Smoker Multiple stents Renal impairment Advanced age Primary PCI is the treatment

What does Surgery do ?? Surgery Sympathetic response Inflammatory mediators Platelet aggregation Vasospasm Decreased fibrinolysis Prothrombotic Pain and anxiety – tachy and hypertension Withheld DAPT !!

Anesthetic goals Anxiolysis Minimal stress response Good analgesia Myocardial balance

Myocardial oxygen balance DECREASE O2 SUPPLY Decreased CBF tachycardia hypotension increased preload hypocapnia ↓ Oxygen content anemia Hypoxemia decreased release – ODC - Lt INCREASED O2 DEMAND Tachycardia Increased wall tension ↑ preload ↑ afterload Increased contractility

In the OT Ready for stent thrombosis and urgent PCI Then we may need extra antiplatelets (Problem of RA) Or ready for transfusions Two IV lines, blood ready Platelet transfusions four hours prior may help in critical cases– stents can adsorb newer platelets – dangerous

Neuro surgery and spine Prostate Eye Middle ear Bleeding is a danger

Monitoring ECG leads properly fixed Elevated troponin levels But TEE is the monitor of choice to detect early RWMAs Coagulation status

Control Diabetes Hypertension COPD Parkinson Other anti ischemic drugs

Minor bleeding after surgery Continue antiplatelet therapy. Perform coagulation tests. Check platelet function Major – communicate with cardio, surgeon Possible only aspirin, after monitoring

Aspirin and clopidogrel resistance 10 – 20 % Impedance aggregometry, platelet function analysis and thrombo-elastography But platelet function analysis and bleeding don’t go together

Five components

Summary Balloon angioplasty alone or BMS or DES Urgent or elective Risk of thrombosis or not Risk for bleeding or not Continue DAPT or bridge or stop Ready for PCI and blood transfusion – monitor ECG, TEE Consider co morbidities and optimize Anxiolysis, myocardial oxygen balance, analgesia, stress reduction, superficial nerve blocks post op follow up